Volume 149, Issue 2, Pages 350-355.e2 (August 2015) Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis Johannan F. Brandse, Gijs R. van den Brink, Manon E. Wildenberg, Desiree van der Kleij, Theo Rispens, Jeroen M. Jansen, Ron A. Mathôt, Cyriel Y. Ponsioen, Mark Löwenberg, Geert R.A.M. D’Haens Gastroenterology Volume 149, Issue 2, Pages 350-355.e2 (August 2015) DOI: 10.1053/j.gastro.2015.04.016 Copyright © 2015 AGA Institute Terms and Conditions
Figure 1 Infliximab concentrations in fecal supernatant 14 days after the first infliximab infusion. Gastroenterology 2015 149, 350-355.e2DOI: (10.1053/j.gastro.2015.04.016) Copyright © 2015 AGA Institute Terms and Conditions
Figure 2 Fecal infliximab concentrations up to 14 days after IFX therapy for clinical response at week 2, endoscopic response at week 8 and clinical response at 3 months. IFX: infliximab, CR: clinical response, NR: non-response, ER: endoscopic response, w2: week 2, w8: week 8, 3m: 3 months. Gastroenterology 2015 149, 350-355.e2DOI: (10.1053/j.gastro.2015.04.016) Copyright © 2015 AGA Institute Terms and Conditions
Supplementary Figure 1 Correlation of fecal IFX concentration at day 1 and serum infliximab concentration at week 2 (before second infusion). Gastroenterology 2015 149, 350-355.e2DOI: (10.1053/j.gastro.2015.04.016) Copyright © 2015 AGA Institute Terms and Conditions